… LDK378 and the antiproliferative activity to xenograft tumor … ALK degrader B3 with in vitro
and in vivo anti-cancer activities … of PROTAC BCL-XL degraders as potent anticancer agents …

… MD-224 was found to achieve complete and durable … selectively binds to the p53 site on
the surface of MDM2 stabilizing p53 and degrading target protein with better anti-cancer activity. …

… to selectively degrade target proteins. Recent progress in the … protein degradation are mostly
achieved via biomacromolecules. … and risks of this emerging PROTAC technology in clinical …

… -targeting chimera (PROTAC) concept. This work has led to the discovery of potent and
effective SHP2 degraders, exemplified by SHP2-D26. SHP2-D26 achieves DC 50 values of 6.0 …

… of a PROTAC (top) and the mechanism of PROTAC-mediated target degradation (bottom).
Interaction of the PROTAC … strongly ablated BTK degrading activity. Fluorescence resonance …

… Bcl-xL targeted PROTAC enhanced anti-cancer effects on … can achieve tissue selectivity,
improve activity and safety, and … -encapsulated Bcl-xL degrading PROTAC was developed, …

… the prevented Bcl-xL degradation … the Bcl-xL degradation caused by the pro-Supra-PROTAC.
In addition, to confirm the capability of the pro-Supra-PROTAC to selectively degrade Bcl-xL…

… tumor-targeting element and an anticancer therapeutic agent. … BET-PROTAC into breast
cancer cells for degrading BRD4 … -constructed PROTAC could achieve targeted antitumor activity …

… for degrading various protein targets (24). For example, our group has 104 developed a
tissue-selective PROTAC for degrading BCL-XL … that PROTAC degrader may achieve 577 long-…

… to specifically target BCL-xL and exhibit increased antitumor activity and reduced platelet …
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat. Med…